Having trouble accessing articles? Reset your cache.

Zyclara imiquimod: Phase IIIb data

In a U.S. and Canadian Phase IIIb trial in 260 patients, Zyclara following cryosurgery met the primary endpoint of significantly reducing the median number of total AK lesions from baseline to week

Read the full 324 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE